2023 Breakfast Briefings
June 9th, 2023 

Supported through an independent educational grant from Merck.

Abstract Info

Venetoclax-Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia: 6-Year Results of the Randomized CLL14 Study

Number: S145

Author: Othman Al-Sawaf

Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor (CTBKI) Pre-Treated Chronic Lymphocytic Leukemia (CLL) Patients: Results from the Phase I/II Bruin Study

Number: S146

Author: Jennifer R. Brown

Abstract (pdf)

Efficacy and Safety Results of MOLTO, a Multicenter, Open Label, Phase II Clinical Trial Evaluating Venetoclax, Atezolizumab and Obinutuzamab Combination in Richter Syndrome

Number: S147

Author: Anna Maria Frustaci

Abstract (pdf)

Other malignancies in the history of CLL: The final analysis of the international multicenter study conducted by ERIC, in HARMONY

Number: S149

Author: Thomas Chatzikonstantinou

Abstract (pdf) 

Moderator

Moderator-Ghia

Paolo Ghia, MD, PhD

Full Professor, Medical Oncology

Director, Strategic Research Program on CLL

Deputy Chairman, Experimental Oncology Division Head, B-Cell

Neoplasia Unit

Università Vita-Salute San Raffaele

RCCS Ospedale San Raffaele

Milano, Italy